Compare Amgen, Inc. (AMGN) vs Amplify Cybersecurity ETF (HACK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Amplify Cybersecurity ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Amplify Cybersecurity ETF trades at $108.97. The key difference: Amgen, Inc. pays a 2.77% dividend while Amplify Cybersecurity ETF pays none, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Amgen, Inc. nearer its low. Which is the better fit depends on your goals.
| AMGN | HACK | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $111.88 |
52-Week Low | $271.18 | $70.69 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
HACK trades at $108.98, down 2.59% on the day but maintains a bullish technical outlook with strong moving average support. The cybersecurity ETF benefits from accelerating industry spending exceeding $300 billion in 2026, driven by AI-powered threats and regulatory requirements. Recent momentum has pushed the fund to 52-week highs, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive as cybersecurity becomes essential infrastructure, with AI-driven attacks creating sustained demand. Key risks include sector rotation and valuation concerns after recent gains. Analyst sentiment favors cybersecurity exposure given the structural growth tailwinds and increasing enterprise budget allocations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →
